Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 9/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 5/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 1.00 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.90 |
| ▸ | AKT1 | P31749 | 1/20 | 0.90 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ins(1,4,5)P3 SCHEMBL9383914 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4871682 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL28087353 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL9382320 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL10490812 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4321735 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL381458 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL382820 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4874594 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19532798 | 0.94 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3717 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171496-A1 | FUSION PEPTIDE FOR REGULATING ACTIVATION OF MAM AND USE THEREOF | UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY (KR) | 2025-05-29 | — | — | US | claimed |
| US-20240024365-A1 | POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20240002473-A1 | MEMBRANE PROTEIN TARGETING ENGINEERED DEUBIQUITINASES AND METHODS OF USE THEREOF | FLUX THERAPEUTICS, INC. | 2024-01-04 | — | — | US | claimed |
| WO-2023235773-A1 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF CHRONIC SPONTANEOUS URTICARIA | GENENTECH, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310471-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| EP-4240754-A1 | MEMBRANE PROTEIN TARGETING ENGINEERED DEUBIQUITINASES AND METHODS OF USE THEREOF | Flux Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2023157824-A1 | METHOD FOR DETERMINING WHETHER ASC IS INCLUDED AT HIGH PURITY IN ADIPOSE TISSUE-DERIVED CELL POPULATION | 慶應義塾 | 2023-08-24 | — | — | WO | claimed |
| US-20230248809-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-08-10 | — | — | US | claimed |
| WO-2023150617-A2 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-08-10 | — | — | WO | claimed |
| WO-1996024846-A1 | HUMAN T CELL INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1996-08-15 | — | — | WO | claimed |
| EP-0657029-A4 | CALCIUM RECEPTOR ACTIVE MOLECULES. | NPS PHARMA INC (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0661982-A1 | METHOD FOR ANTAGONIZING INOSITOL 1,4,5-TRIPHOSPHATE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-12 | — | — | EP | claimed |
| EP-0657029-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | claimed |
| WO-1994018959-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1994007507-A1 | METHOD FOR ANTAGONIZING INOSITOL 1,4,5-TRIPHOSPHATE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-04-14 | — | — | WO | claimed |
| WO-1993004373-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | claimed |
| EP-0434706-A4 | METHOD AND KIT FOR DIAGNOSIS OF MALIGNANT HYPERPYREXIA | — | 1992-01-22 | — | — | EP | claimed |
| EP-0434706-A1 | METHOD AND KIT FOR DIAGNOSIS OF MALIGNANT HYPERPYREXIA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1991-07-03 | — | — | EP | claimed |
| WO-1990002201-A1 | METHOD AND KIT FOR DIAGNOSIS OF MALIGNANT HYPERPYREXIA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1990-03-08 | — | — | WO | claimed |